CRIS Current Research Information System

BIASCO, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.349
EU - Europa 11.547
AS - Asia 10.754
AF - Africa 892
SA - Sud America 776
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 12
Totale 41.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.188
GB - Regno Unito 3.430
SG - Singapore 3.423
CN - Cina 3.126
VN - Vietnam 2.241
DE - Germania 1.428
IT - Italia 1.406
SE - Svezia 1.326
HK - Hong Kong 793
RU - Federazione Russa 726
IN - India 664
BR - Brasile 573
IE - Irlanda 546
UA - Ucraina 527
CH - Svizzera 521
FR - Francia 499
ZA - Sudafrica 296
NL - Olanda 269
EE - Estonia 247
TG - Togo 225
FI - Finlandia 153
CI - Costa d'Avorio 151
JP - Giappone 136
CA - Canada 106
SC - Seychelles 98
BG - Bulgaria 97
JO - Giordania 94
AT - Austria 86
NG - Nigeria 85
AR - Argentina 83
BE - Belgio 70
ID - Indonesia 53
PL - Polonia 49
GR - Grecia 43
KR - Corea 43
MX - Messico 43
IR - Iran 42
EC - Ecuador 39
CL - Cile 33
AU - Australia 24
BD - Bangladesh 22
RO - Romania 19
TR - Turchia 19
LT - Lituania 18
PY - Paraguay 18
ES - Italia 17
HR - Croazia 17
MY - Malesia 16
CO - Colombia 15
LB - Libano 15
CZ - Repubblica Ceca 10
IQ - Iraq 10
PT - Portogallo 10
EG - Egitto 9
UZ - Uzbekistan 9
PE - Perù 8
SK - Slovacchia (Repubblica Slovacca) 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AE - Emirati Arabi Uniti 6
KZ - Kazakistan 6
TN - Tunisia 6
DO - Repubblica Dominicana 5
IL - Israele 5
NZ - Nuova Zelanda 5
SA - Arabia Saudita 5
DZ - Algeria 4
HU - Ungheria 4
MU - Mauritius 4
NO - Norvegia 4
NP - Nepal 4
DK - Danimarca 3
GE - Georgia 3
KE - Kenya 3
MK - Macedonia 3
PH - Filippine 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CM - Camerun 2
EU - Europa 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
MA - Marocco 2
MD - Moldavia 2
PA - Panama 2
TH - Thailandia 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
CD - Congo 1
DM - Dominica 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
JM - Giamaica 1
KH - Cambogia 1
Totale 41.343
Salva come PNG Salva come JPEG
Città #
Southend 3.142
Singapore 2.171
Fairfield 1.888
Ashburn 1.728
Chandler 1.488
Woodbridge 937
Wilmington 930
Houston 876
Dong Ket 821
Seattle 789
Hong Kong 785
Santa Clara 765
Princeton 690
Cambridge 627
Ann Arbor 584
Beijing 508
Bern 499
Dublin 492
Boardman 383
Jacksonville 302
Nanjing 302
Westminster 296
Ho Chi Minh City 287
Padova 282
Bologna 278
New York 241
Lomé 225
Hanoi 217
Los Angeles 200
Dallas 192
Berlin 177
Jinan 168
Hefei 154
Abidjan 151
Shenyang 141
Saint Petersburg 140
Helsinki 138
Tokyo 133
Medford 120
San Diego 120
Buffalo 114
Menlo Park 112
Changsha 103
Nanchang 101
Redondo Beach 99
Sofia 97
Amman 93
Milan 92
Hebei 91
Turin 88
Mülheim 86
Jiaxing 82
Abeokuta 73
Tianjin 68
São Paulo 66
Frankfurt am Main 64
Brussels 62
Florence 62
Dearborn 60
Guangzhou 60
Falls Church 59
Zhengzhou 57
Hangzhou 55
Redmond 54
Shanghai 54
Des Moines 53
Vienna 52
Toronto 51
Kuban 49
Yubileyny 49
Norwalk 48
Bremen 45
Taiyuan 43
Chicago 42
Phoenix 40
Taizhou 40
Seoul 39
Munich 38
Warsaw 38
Rome 37
Fremont 36
Haiphong 36
Ningbo 36
Haikou 35
Olalla 35
Redwood City 35
Bühl 33
Mahé 33
Lanzhou 32
Kunming 31
London 28
San Francisco 28
San Venanzo 28
Wuhan 28
Falkenstein 27
Jakarta 27
Pune 27
Nuremberg 26
Orem 26
Mountain View 23
Totale 27.593
Salva come PNG Salva come JPEG
Nome #
The National Tumor Association Foundation (ANT): A 30 year old model of home palliative care. 503
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 373
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 365
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 276
The 'surprise' question in advanced cancer patients: A prospective study among general practitioners. 241
A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. 241
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 238
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 236
Cardiac metastasis of melanoma. 231
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 231
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 230
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 227
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 220
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 217
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 216
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 215
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 214
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 210
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 209
Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. 208
A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. 206
Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice 199
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 198
Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer 196
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 193
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 192
Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading 192
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 192
Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. 191
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure 190
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 189
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 189
Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis 189
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 187
HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report 186
Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma 186
Autoimmune pancreatitis associated with high levels of chromogranin a, serotonin and 5-hydroxyindoleacetic Acid 185
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. 185
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? 184
Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis. 184
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 184
Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). 182
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) 182
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. 182
Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. 181
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 181
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease 179
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 179
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 178
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. 176
Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. 176
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 176
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. 175
Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. 175
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. 174
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 173
Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression 173
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. 173
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). 171
ACTIVATED NF-KB IN COLORECTAL CANCER: PREDICTIVE OR PROGNOSTIC FACTOR? 171
In Reply 171
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 171
Treatment of colorectal cancer liver metastases 168
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 168
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 166
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib. 165
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 165
An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild type gastrointestinal stromal tumours - Letter to the editor. 164
Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. 163
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice 162
HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma 162
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study 161
Cell proliferation and differentiation in familial adenomatous polyposis (FAP). 160
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 160
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 160
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 160
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 159
GemOx and Ovarian Pancreatic Cancer Metastasis (PC) 159
Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. 159
State of the art biological therapies in pancreatic cancer 157
Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. 156
Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review. 156
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 156
MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype. 155
Spontaneous regression of a desmoid intraabdominal tumor in a patient affected by familial adenomatous polyposis. 154
11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. 154
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 154
An online international comparison of thresholds for triggering a negative response to the "Surprise Question": a study protocol 153
Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors 152
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 152
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? 152
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib 152
An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST) 152
Urease-Positive Bacteria Other than Helicobacter pylori in Human Gastric Juice and Mucosa 150
Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. 150
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 150
Risk Factors in Resected Pancreatic Cancer. A Single Centre Experience 149
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries 149
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 148
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma 148
Totale 18.757
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.934 0 0 0 0 0 245 54 228 488 192 191 1.536
2021/20226.010 614 258 322 437 527 299 152 349 279 424 1.272 1.077
2022/20236.568 740 950 334 814 384 418 144 387 1.026 192 524 655
2023/20241.667 165 276 71 190 132 419 77 110 45 87 51 44
2024/20255.776 207 967 476 432 1.218 289 414 169 48 416 123 1.017
2025/20266.609 1.193 934 1.211 936 1.600 735 0 0 0 0 0 0
Totale 42.181